Literature DB >> 7840599

In vitro activity of DU-6859a against anaerobic bacteria.

H M Wexler1, E Molitoris, D Reeves, S M Finegold.   

Abstract

The activity of a new quinolone agent, DU-6859a, against 330 strains of anaerobic bacteria was determined by using the National Committee for Clinical Laboratory Standards-approved Wadsworth brucella laked blood agar method; the activity of DU-6859a was compared with those of amoxicillin-clavulanate (2:1), chloramphenicol, ciprofloxacin, clindamycin, fleroxacin, imipenem, lomefloxacin, metronidazole, sparfloxacin, and temafloxacin. DU-6859a and chloramphenicol inhibited all of the isolates at concentrations of 1 and 16 micrograms/ml, respectively; amoxicillin-clavulanate, imipenem, and metronidazole inhibited > or = 94% of the isolates at their respective breakpoints (8, 8, and 16 micrograms/ml). MICs of DU-6859a at which 90% of the strains were susceptible were 1 to 5 twofold dilutions lower than those of the other quinolones for every group of organisms. MICs of DU-6859a at which 90% of the strains were susceptible (total numbers of strains tested are in parentheses) were < or = 0.25 micrograms/ml for Bacteroides fragilis (57), other B. fragilis group species (84), Bilophila wadsworthia (15), Clostridium species (27) (including C. difficile, C. perfringens, and C. ramosum), Fusobacterium nucleatum (16), Fusobacterium mortiferum-F. varium group species (10), Peptostreptococcus species (20), non-spore-forming gram-positive rods (20), and Prevotella species (25).

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7840599      PMCID: PMC284775          DOI: 10.1128/AAC.38.10.2504

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  5 in total

1.  In-vitro comparison of DU-6859a, a novel fluoroquinolone, with other quinolones and oral cephalosporins tested against 5086 recent clinical isolates.

Authors:  S A Marshall; R N Jones; P R Murray; J A Washington; S D Allen; E H Gerlach; M E Erwin
Journal:  J Antimicrob Chemother       Date:  1993-12       Impact factor: 5.790

2.  Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates.

Authors:  K Sato; K Hoshino; M Tanaka; I Hayakawa; Y Osada
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

3.  In vitro activity of Bay Y3118 against anaerobic bacteria.

Authors:  H M Wexler; E Molitoris; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

4.  In vitro activities of three of the newer quinolones against anaerobic bacteria.

Authors:  H M Wexler; E Molitoris; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

5.  In vitro activity of DU-6859a, a new fluorocyclopropyl quinolone.

Authors:  S A Marshall; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

  5 in total
  10 in total

1.  In vitro activities of gatifloxacin, two other quinolones, and five nonquinolone antimicrobials against obligately anaerobic bacteria.

Authors:  R Schaumann; G Ackermann; B Pless; M C Claros; A C Rodloff
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

2.  In vitro activities of Y-688, a new 7-substituted fluoroquinolone, against anaerobic bacteria.

Authors:  A P MacGowan; K E Bowker; M Wootton; H A Holt; D S Reeves
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

3.  Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes.

Authors:  K E Aldridge; D S Ashcraft
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

4.  Comparative in vitro activities of DU-6859a, levofloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against 387 aerobic and anaerobic bite wound isolates.

Authors:  E J Goldstein; D M Citron; S Hunt Gerardo; M Hudspeth; C V Merriam
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

5.  In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria.

Authors:  H M Wexler; E Molitoris; D Molitoris; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

Review 6.  Quinolone activity against anaerobes.

Authors:  P C Appelbaum
Journal:  Drugs       Date:  1999       Impact factor: 9.546

7.  In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates.

Authors:  D Milatovic; F J Schmitz; S Brisse; J Verhoef; A C Fluit
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

8.  Bactericidal activity of DU-6859a compared to activities of three quinolones, three beta-lactams, clindamycin, and metronidazole against anaerobes as determined by time-kill methodology.

Authors:  S K Spangler; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

Review 9.  Bacteroides: the good, the bad, and the nitty-gritty.

Authors:  Hannah M Wexler
Journal:  Clin Microbiol Rev       Date:  2007-10       Impact factor: 26.132

Review 10.  Biological Effects of Quinolones: A Family of Broad-Spectrum Antimicrobial Agents.

Authors:  Ana R Millanao; Aracely Y Mora; Nicolás A Villagra; Sergio A Bucarey; Alejandro A Hidalgo
Journal:  Molecules       Date:  2021-11-25       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.